Immunovant, Inc. (IMVT)
26.72
-0.36
(-1.33%)
USD |
NASDAQ |
Mar 05, 16:00
26.72
0.00 (0.00%)
After-Hours: 16:28
Immunovant Research and Development Expense (Annual) : 360.92M for March 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Boston Scientific Corp. | 2.052B |
| Viridian Therapeutics, Inc. | 338.47M |
| Plus Therapeutics, Inc. | 10.58M |
| Nutriband, Inc. | 3.119M |
| Definium Therapeutics, Inc. | 117.66M |